摘要
目的分析血清中可溶性晚期糖基化终末产物受体(sRAGE)与肺癌的相关性。方法将辽宁省人民医院2015年5月-2018年12月收治的102例肺癌患者纳入本研究,另将同期到我院体检的100例健康体检者作为对照组,应用酶联免疫吸附法(ELISA)测定两组血清sRAGE水平,分析肺癌患者与健康对照者血清sRAGE水平差异及血清sRAGE水平与肺癌患者临床病理特征的相关性,并采用受试者工作特征曲线(ROC)评价血清sRAGE在肺癌中的诊断效能。结果ELISA检测结果显示,肺癌组血清sRAGE水平[(632.56±203.14)ng/L]明显低于健康对照组[(976.02±283.57)ng/L],二者相比差异具有统计学意义(t=9.879,P<0.05)。血清sRAGE水平与肺癌患者的分化程度、TNM分期、淋巴转移及远端转移密切相关(P<0.05),而与患者的性别、年龄、肿瘤直径及病理分型无明显关系(P>0.05)。采用ROC曲线评价血清sRAGE对肺癌的诊断效能,结果显示,ROC曲线下面积为0.851(95%CI:0.620-0.982),筛选其最佳截断点:当sRAGE为503.39 ng/L时,敏感性为91.39%,特异性为81.42%。结论sRAGE在肺癌患者血清中表达下调,血清sRAGE水平与肺癌患者的分化程度、TNM分期、淋巴转移及远端转移密切相关,血清sRAGE对肺癌的诊断敏感性和特异性较高,提示sRAGE可能与肺癌的发生及恶性程度有关,检测血清sRAGE可能对肺癌早期诊断有一定价值。
Objective To analyze the correlation between soluble advanced glycation end product receptor(sRAGE)in serum and lung cancer.Methods 102 lung cancer patients admitted to our hospital from May 2015 to December 2017 were enrolled in this study.Another 100 healthy examination people in our hospital during the same period were taken as the control group.The serum sRAGE levels were measured by enzyme-linked immunosorbent assay(ELISA).The difference of serum sRAGE level between lung cancer patients and healthy controls and the correlation between serum sRAGE level and clinicopathological characteristics of lung cancer patients were analyzed.The diagnostic efficacy of serum sRAGE in lung cancer was evaluated by ROC.Results The results of ELISA showed that the serum sRAGE level[(632.56±203.14)ng/L]in the lung cancer group was significantly lower than that in the healthy control group[(976.02±283.57)ng/L],and there was a significant difference between the two groups(t=9.879,P<0.05).The serum sRAGE level was closely related to differentiation degree,TNM stage,lymphatic metastasis and distal metastasis of lung cancer patients(P<0.05),but not to gender,age,tumor diameter and pathological classification(P>0.05).The ROC curve was used to evaluate the diagnostic efficacy of serum sRAGE for lung cancer.The results showed that the area under the ROC curve was 0.851(95%CI:0.620-0.982).The best cut-off point was selected:when sRAGE was 503.39 ng/L,the sensitivity was 91.39%,and the specificity was 81.42%.Conclusion The expression of sRAGE in serum of patients with lung cancer is down-regulated.Serum sRAGE level is closely related to differentiation degree,TNM stage,lymphatic metastasis and distal metastasis of lung cancer.Serum sRAGE has high sensitivity and specificity in the diagnosis of lung cancer,suggesting that sRAGE may be related to the occurrence and malignancy of lung cancer.Detection of serum sRAGE may be of value in early diagnosis of lung cancer.
作者
李宝亮
佟平丽
LI Bao-liang;TONG Ping-li(Department of Emergency Medicine,People's Hospital of Liaoning Province,Shenyang,Liaoning 110016,China)
出处
《临床肺科杂志》
2019年第11期2027-2030,共4页
Journal of Clinical Pulmonary Medicine
